NCT05906134 Minimally Invasive Esophagectomy Pain Control Trial
| NCT ID | NCT05906134 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Swedish Medical Center |
| Condition | Postoperative Pain, Acute |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-04-26 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2022-04-26 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A pilot randomized controlled trial comparing intercostal nerve blocks, cryo-ablation plus intercostal nerve blocks, and serratus plane catheter plus intercostal nerve blocks in patients undergoing esophagectomies with minimally invasive thoracic approaches.
Eligibility Criteria
Inclusion Criteria: All adult individuals who undergo an esophagectomy with an intended minimally invasive approach of the chest at Swedish Medical Center-First Hill. These approaches include: * 3-hole with R video-assisted thoracoscopic surgery (VATS) * Ivor Lewis R VATS Exclusion Criteria: * Age \<18 * Unable to consent * Additional surgical procedures planned * Patients with previous thoracic surgery * Patient with chronic pain on a daily regimen of narcotics * Non-English speaking * Contraindications to neuraxial anesthesia (ongoing anticoagulation, anticipated post-operative therapeutic anticoagulation, spinal cord stimulators, anatomic abnormalities preventing epidural placement)
Contact & Investigator
Brian Louie, M.D.
PRINCIPAL INVESTIGATOR
Swedish Cancer Institute
Frequently Asked Questions
Who can join the NCT05906134 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Postoperative Pain, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05906134 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05906134 currently recruiting?
Yes, NCT05906134 is actively recruiting participants. Contact the research team at brian.louie@swedish.org for enrollment information.
Where is the NCT05906134 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT05906134 clinical trial?
NCT05906134 is sponsored by Swedish Medical Center. The principal investigator is Brian Louie, M.D. at Swedish Cancer Institute. The trial plans to enroll 30 participants.